Aurora Cannabis Inc. has been granted two licenses by Germany's Federal Institute for Drugs and Medical Devices (BfArM) under the new Medical Cannabis Act. The expanded cultivation license allows Aurora to continue domestic production and add an approved product, while a dedicated R&D license permits trials of up to seven novel cultivars at their EU GMP facility in Leuna.Since 2021, Aurora's Leuna facility has been producing approximately 1,000 kg of medical cannabis flower annually under a tender agreement with BfArM. The new licenses reflect Aurora's commitment to quality and compliance, positioning the company to meet growing patient demand in Germany's expanding medical cannabis market.Michael Simon, President of Aurora Europe, emphasized the company's leadership in the region and its dedication to providing high-quality cannabis. Aurora views these developments as part of a broader trend towards medical cannabis acceptance and regulatory reform across Europe, aligning with their global strategy to improve patient access to medical cannabis.

Aurora Cannabis Inc. has been granted two licenses by Germany's Federal Institute for Drugs and Medical Devices (BfArM) under the new Medical Cannabis Act. The expanded cultivation license allows Aurora to continue domestic production and add an approved product, while a dedicated R&D license permits trials of up to seven novel cultivars at their EU GMP facility in Leuna.Since 2021, Aurora's Leuna facility has been producing approximately 1,000 kg of medical cannabis flower annually under a tender agreement with BfArM. The new licenses reflect Aurora's commitment to quality and compliance, positioning the company to meet growing patient demand in Germany's expanding medical cannabis market.Michael Simon, President of Aurora Europe, emphasized the company's leadership in the region and its dedication to providing high-quality cannabis. Aurora views these developments as part of a broader trend towards medical cannabis acceptance and regulatory reform across Europe, aligning with their global strategy to improve patient access to medical cannabis.